I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

The article highlights Johnson & Johnson’s dividend strength and resiliency, noting an expected FY2026 revenue of $100.6B (midpoint), +6.8% YoY, despite a Stelara patent cliff that previously drove ~12% of net sales. It also cites an S&P AAA credit rating and a 64-year Dividend King streak of annual payout increases, alongside a payout ratio just under 47% and a ~2% forward dividend yield (above the S&P 500’s ~1.1%). While acknowledging ongoing talc litigation risk, the piece says J&J has moved closer to resolving most lawsuits, making the stock “more attractive” for dividend investors.

Analysis

JNJ is less a dividend story than a volatility story: the investable edge is the potential collapse in equity risk premium if the legal overhang is finally converted from an open-ended tail into a known liability. That matters because the stock already trades like a quality bond proxy; once the litigation cloud clears, incremental upside is likely to come from multiple stability rather than a big earnings inflection.

The first-order beneficiary is JNJ’s own capital allocation flexibility, but the second-order beneficiaries are higher-beta healthcare names with similar legal or patent overhangs if investors reprice the entire defensive basket. The risk is that the market is already giving credit for “resolution soon,” while the actual settlement mechanics could still drag on and consume cash that would otherwise go to buybacks or M&A.

Time horizon matters: over days, this is mostly a sentiment trade and likely modest; over 1-3 months, the catalyst is confirmation of settlement terms and forward guidance on free cash flow; over 6-18 months, the real question is whether low-teens quality multiples can expand for a no-growth defensive compounder in a rising-rate regime. If real yields back up, JNJ’s dividend safety may protect the downside but won’t necessarily drive relative outperformance.

Contrarian view: the market may be underestimating how little yield there is here for a stock that still carries some residual legal and regulatory headline risk. The dividend is safe, but the setup may be more suitable for capital preservation than alpha generation; if the settlement is clean, the upside is probably incremental, not transformative. What would falsify the thesis is a delayed or materially more expensive litigation resolution, or a guide that shows price negotiations and patent losses are compressing 2026-2027 earnings more than expected.

Key Decisions for Investors

• Hold/overweight JNJ only as a defensive core position, not as a high-conviction alpha idea; expect low-single-digit relative upside over 3-6 months if litigation is formally resolved without a balance-sheet surprise.
• Pair trade: long JNJ / short BMY on a 1-3 month horizon if you want healthcare quality with lower legal and payout risk; JNJ should screen better if the market rewards balance-sheet durability and dividend safety.
• Do not chase the stock after resolution headlines; wait for post-event volatility and look for entry on a 2-4% pullback or on confirmation that buyback/dividend capacity remains intact.
• Set an alert around the next earnings/guidance update: if management does not reaffirm the revenue/Fcf path after legal clarity, the re-rating thesis is likely already priced in.
• If rates re-accelerate higher, rotate away from JNJ into faster-growing healthcare or stay in cash-equivalent defensives; JNJ’s yield is too low to fully offset duration risk.